EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Effective as of January 1, 2018, (the “Effective Date”), the Compensation Committee of the Board of Directors (the “Committee”) of EyeGate Pharmaceuticals, Inc. (the “Company”) promoted Sarah M. Romano, CPA to Chief Financial Officer of the Company. Prior to her promotion, Ms. Romano served as the Company’s Interim Chief Financial Officer since February 1, 2017.
Ms. Romano joined the Company as Corporate Controller in 2016, and has been responsible for the Company’s accounting, tax, financial reporting, and internal controls. Prior to joining the Company, Ms. Romano served as Assistant Controller at TechTarget from June 2015 through August 2016 and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm, from September 2013 through May 2015. Previously, she held financial reporting positions of increasing responsibility at SoundBite Communications from 2008 until its acquisition by Genesys in 2013, serving as Senior Financial Reporting Analyst from 2008 to 2010, as Financial Reporting Supervisor from 2010 to 2011 and as Financial Reporting Manager from 2011 to 2013. Ms. Romano also served as a Senior Financial Reporting Analyst at Cognex Corporation, a publicly-traded manufacturer of machine vision systems, software and sensors, from 2004 through 2008. Ms. Romano began her career as an Auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and Masters of Accounting from Boston College.
On the Effective Date, the Company entered into a new offer letter with Ms. Romano. to this letter, Ms. Romano will receive an annual base salary of $200,000 and is entitled to receive a bonus of up to 25% of her annual base salary for the applicable fiscal year.
The foregoing description of Ms. Romano’s offer letter is a summary and does not purport to be complete. Such description is qualified in its entirety by reference to the text of the offer letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
There are no related party transactions between the Company and Ms. Romano, and Ms. Romano is neither related to, nor does she have any relationship with, any existing member of the Board or any executive officer of the Company.
On January 4, 2018, the Company issued a press release announcing the promotion of Ms. Romano to Chief Financial Officer. A copy of the press release is filed herewith as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
The Company hereby files the following exhibits:
| 99.1 | Press Release of the Company. |
| # | Management contract or compensatory plan or arrangement. |
EYEGATE PHARMACEUTICALS INC ExhibitEX-10.1 2 tv482569_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 271 Waverly Oaks Road,…To view the full exhibit click here
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
